BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Clinical Outcome
58 results:

  • 1. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
    Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
    Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. clinical Relevance of Mortalin in Ovarian cancer Patients.
    Rajtak A; Czerwonka A; Pitter M; Kotarski J; Okła K
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899836
    [No Abstract]    [Full Text] [Related]  

  • 3. clinical outcome and Treatment Sequences of Patients with Advanced Pancreatic cancer Treated with Contemporary Chemotherapy Protocols.
    Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
    Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
    Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
    ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
    [TBL] [Abstract] [Full Text] [Related]  

  • 5.
    Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
    Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Accuracy and other quality indicators of solid pancreatic mass endoscopic ultrasound-guided fine needle aspiration and biopsy in two academic endoscopy centers.
    Figueiredo M; Arvanitakis M; Zaarour A; Toussaint E; Devière J; Van Laethem JL; Gomez-Galdon M; Verset L; Demetter P; Eisendrath P
    Acta Gastroenterol Belg; 2021; 84(3):451-455. PubMed ID: 34599570
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Importance of Enhanced Recovery After Surgery (ERAS) Protocol Compliance for Length of Stay in Ovarian cancer Surgery.
    Sánchez-Iglesias JL; Gómez-Hidalgo NR; Pérez-Benavente A; Carbonell-Socias M; Manrique-Muñoz S; Serrano MP; Gutiérrez-Barceló P; Bradbury M; Nelson G; Gil-Moreno A
    Ann Surg Oncol; 2021 Dec; 28(13):8979-8986. PubMed ID: 34091804
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
    Canzler U; Lück HJ; Neuser P; Sehouli J; Burges A; Harter P; Schmalfeldt B; Aminossadati B; Mahner S; Kommoss S; Wimberger P; Pfisterer J; de Gregorio N; Hasenburg A; Gropp-Meier M; El-Balat A; Jackisch C; du Bois A; Meier W; Wagner U
    Arch Gynecol Obstet; 2020 May; 301(5):1267-1274. PubMed ID: 32277253
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
    Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
    Kessous R; Wissing MD; Piedimonte S; Abitbol J; Kogan L; Laskov I; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    Acta Obstet Gynecol Scand; 2020 Jul; 99(7):933-940. PubMed ID: 31954071
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China.
    Ni J; Cheng X; Zhou R; Xu X; Guo W; Chen X
    J Ovarian Res; 2019 Nov; 12(1):117. PubMed ID: 31775908
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Radioguided occult lesion localization in patients with recurrent thyroid cancer.
    Tuncel M; Süslü N
    Eur Arch Otorhinolaryngol; 2019 Jun; 276(6):1757-1766. PubMed ID: 30887167
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
    Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
    Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
    George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
    BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. LINE-1 methylation level and prognosis in pancreas cancer: pyrosequencing technology and literature review.
    Yamamura K; Kosumi K; Baba Y; Harada K; Gao F; Zhang X; Zhou L; Kitano Y; Arima K; Kaida T; Takeyama H; Higashi T; Imai K; Hashimoto D; Chikamoto A; Tan X; Baba H
    Surg Today; 2017 Dec; 47(12):1450-1459. PubMed ID: 28536860
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Plasma Cytokines Correlated With Disease Characteristics, Progression-Free Survival, and Overall Survival in Testicular Germ-Cell Tumor Patients.
    Svetlovska D; Miskovska V; Cholujova D; Gronesova P; Cingelova S; Chovanec M; Sycova-Mila Z; Obertova J; Palacka P; Rajec J; Kalavska K; Usakova V; Luha J; Ondrus D; Spanik S; Mardiak J; Mego M
    Clin Genitourin Cancer; 2017 Jun; 15(3):411-416.e2. PubMed ID: 28237180
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma.
    Park JS; Chang JW; Liu L; Jung SN; Koo BS
    Oral Oncol; 2017 Sep; 72():183-187. PubMed ID: 28222967
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Is a second recombinant human thyrotropin stimulation test useful? The value of postsurgical undetectable stimulated thyroglobulin level at the time of remnant ablation on clinical outcome.
    Prior-Sánchez I; Barrera Martín A; Moreno Ortega E; Vallejo Casas JA; Gálvez Moreno MÁ
    Clin Endocrinol (Oxf); 2017 Jan; 86(1):97-107. PubMed ID: 27327536
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. clinical outcome of (131)I Therapy in Differentiated Thyroid cancer with Preablative Thyroglobulin below 10 ng/ml.
    Liu XF; Li J; Zhao T; Hou M; Li H; Liang J; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Feb; 38(1):88-92. PubMed ID: 26956863
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Origin of craniopharyngiomas: implications for growth pattern, clinical characteristics, and outcomes of tumor recurrence.
    Bao Y; Pan J; Qi ST; Lu YT; Peng JX
    J Neurosurg; 2016 Jul; 125(1):24-32. PubMed ID: 26654183
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.